Romania Country Drug Report 2019

Drug-related infectious diseases

In Romania, an increase in the notification of human immunodeficiency virus (HIV) infections among people who inject drugs (PWID) was reported between 2011 and 2013; however, this decreased over the period 2014-17. Recent data based on self-reported HIV status among drug treatment clients suggest that around 16 % reported to be HIV positive. However, self-reported prevalence is likely an underestimate, as some drug users might not know their status. The 2017 seroprevalence study in Bucharest found that 30 % of injectors were HIV positive.

Prevalence of HIV and HCV antibodies among people who inject drugs in Romania (%)
  Region HCV HIV
Data from 2017 (HIV) and from 2015 (HCV).
National : 15.9
Sub-national 75.7 :

Hepatitis C virus (HCV) infection is common among Romanian drug users. The seroprevalence study conducted in 2017 among PWID in Bucharest indicated that more than three quarters tested positive for HCV antibodies and that fewer than 1 in 10 were infected with hepatitis B virus. HIV and HCV co-infections are frequent among PWID in Romania.


Romania main page

Methodological note: Analysis of trends is based only on those countries providing sufficient data to describe changes over the period specified. The reader should also be aware that monitoring patterns and trends in a hidden and stigmatised behaviour like drug use is both practically and methodologically challenging. For this reason, multiple sources of data are used for the purposes of analysis in this report. Caution is therefore required in interpretation, in particular when countries are compared on any single measure. Detailed information on methodology and caveats and comments on the limitations in the information set available can be found in the EMCDDA Statistical Bulletin.